JAZZ 2026 JPM Healthcare Conference Presentation_FINAL.pdf

1、44th Annual J.P.Morgan Healthcare ConferenceJanuary 2026Renee Gala,President&CEORedefining Possibilities in Rare DiseaseThis presentation contains forward-looking statements and financial targets,including,but not limited to,statements related to:the Companys growth prospects and future financial an

2、d operating results,including the ability of the Companys portfolio to drive long-term shareholder value;expectations with respect to indication expansion opportunities;2025 total revenue guidance and 2025 revenue for each of Xywav,Epidiolex and Modeysoand the Companys expectations related thereto;t

3、he Companys ability to drive significant cash flow generation;the Companys commercial expectations,including with respect to revenue diversification and its expectations for significant growth;the Companys expectations with respect to the commercial potential of its products and product candidates,i

4、ncluding the peak potential of zanidatamab and Modeyso,growth opportunities for Epidiolex/Epidyolex,Modeyso,Xywav,Zepzelca and Ziihera,and the potential regulatory paths related thereto;the value and growth potential of its products;the Companys net product sales and goals for net product sales from

5、 new and acquired products;the Companys views and expectations relating to its patent portfolio,including with respect to expected patent protection;planned or anticipated clinical trial events,including with respect to initiations,enrollment and data read-outs,and the anticipated timing thereof,and

6、 planned or anticipated regulatory submissions and filings and other regulatory matters,including potential approvals,including the timing thereof,such as the timing of the supplemental biologics license application for,and launch and approval of,zanidatamab in 1L GEA;and other statements that are n